報價延遲最少15分鐘:2025/02/23 04:12 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.33 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.15/0.45
|
|
企業價值
2.00B
|
| 資產負債 |
|
每股賬面淨值
5.18
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
232.28M
|
|
每股收益
2.75
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 04:12 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |